World's Best Scientists 2026 revealed!
Markku S. Nieminen

Markku S. Nieminen

D-Index & Metrics

Medicine

D-Index
129
Citations
114947
World Ranking
2520
National Ranking
28

Markku S. Nieminen publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Markku S. Nieminen sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 636 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Markku S. Nieminen D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Markku S. Nieminen sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 129 D-Index — 88th percentile

88% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Markku S. Nieminen is affiliated with the University of Helsinki in Finland. Their research primarily focuses on medicine, with a concentration in cardiology and related fields.

Their recent publications cover a variety of topics within cardiovascular medicine and pharmacology. Notable works include:

  • Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol (2021), Journal of the American College of Cardiology
  • Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use (2020), Journal of Cardiovascular Pharmacology
  • Levosimendan Efficacy and Safety: 20 years of SIMDAX in Clinical Use (2020), Cardiac Failure Review
  • Relation of Lipoprotein(a) Levels to Incident Type 2 Diabetes and Modification by Alirocumab Treatment (2021), Diabetes Care
  • Risk of sudden cardiac death associated with QRS, QTc, and JTc intervals in the general population (2022), Heart Rhythm

Their frequent co-authors indicate collaboration with established researchers in cardiovascular medicine, including:

  • Shaun G. Goodman
  • Gregory G. Schwartz
  • Michael Szarek
  • J. Wouter Jukema
  • Robert Pordy

Major publication venues reflect the scientist's focus and include:

  • Journal of the American College of Cardiology
  • Journal of Cardiovascular Pharmacology
  • Cardiac Failure Review
  • Diabetes Care
  • Heart Rhythm

Their work spans a range of subfields and topics within medicine, emphasizing cardiovascular health and related economic evaluations. Main fields of study are:

  • Cardiology and Cardiovascular Medicine
  • Surgery
  • Economics and Econometrics
  • Biomedical Engineering
  • Genetics

Main research topics include:

  • Lipoproteins and Cardiovascular Health
  • Health Systems, Economic Evaluations, Quality of Life
  • Heart Failure Treatment and Management
  • Cardiac Structural Anomalies and Repair
  • Mechanical Circulatory Support Devices
  • Pharmaceutical Economics and Policy
  • Cardiovascular Function and Risk Factors

The scientist's contributions reflect multidisciplinary approaches integrating clinical cardiology, pharmacology, and health economics, advancing understanding in cardiovascular function, treatments, and associated metabolic conditions.

Best Publications

  • Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

    Björn Dahlöf;Richard B Devereux;Sverre E Kjeldsen;Stevo Julius

  • ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).

    Kenneth Dickstein;Alain Cohen-Solal;Gerasimos Filippatos;John J V McMurray

  • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial

    Peter S Sever;Björn Dahlöf;Neil R Poulter;Hans Wedel

  • Biological, clinical and population relevance of 95 loci for blood lipids

    Tanya M. Teslovich;Kiran Musunuru;Albert V. Smith;Andrew C. Edmondson

  • Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology.

    Karl Swedberg;John Cleland;Henry Dargie;Helmut Drexler

  • Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial

    Björn Dahlöf;Peter S Sever;Neil R Poulter;Hans Wedel

  • Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction.

    P Saikku;P Saikku;K Mattila;K Mattila;M.S Nieminen;M.S Nieminen;J.K Huttunen;J.K Huttunen

  • Plasma HDL cholesterol and risk of myocardial infarction: A mendelian randomisation study

    Benjamin F. Voight;Benjamin F. Voight;Benjamin F. Voight;Gina M. Peloso;Gina M. Peloso;Marju Orho-Melander;Ruth Frikke-Schmidt

  • A comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease

    M Nikpay;A Goel;Won H-H.;L M Hall

  • Hundreds of variants clustered in genomic loci and biological pathways affect human height

    Hana Lango Allen;Karol Estrada;Guillaume Lettre;Sonja I. Berndt

  • Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

    Lars H Lindholm;Hans Ibsen;Björn Dahlöf;Richard B Devereux

  • Large-scale association analysis identifies new risk loci for coronary artery disease

    Panos Deloukas;Stavroula Kanoni;Christina Willenborg;Martin Farrall

  • Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.

    Markku S. Nieminen;Silvia G. Priori;Maria Angeles Alonso Garcia;Andrzej Budaj

  • EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population.

    Markku S. Nieminen;Dirk Brutsaert;Kenneth Dickstein;Helmut Drexler

  • Targeted Anticytokine Therapy in Patients with Chronic Heart Failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)

    Douglas L. Mann;John J.V. McMurray;Milton Packer;Karl Swedberg

  • Effect of nesiritide in patients with acute decompensated heart failure.

    C. M. O'Connor;R. C. Starling;A. F. Hernandez;P. W. Armstrong

  • Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure: The SURVIVE Randomized Trial

    Alexandre Mebazaa;Markku S Nieminen;Milton Packer;Alain Cohen-Solal

  • Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End point reduction in hypertension (LIFE) study

    Kristian Wachtell;Mika Lehto;Eva Gerdts;Michael H. Olsen

  • Prognostic significance of left ventricular mass change during treatment of hypertension

    Richard B Devereux;Kristian Wachtell;Eva Gerdts;Krister K. Boman

  • A comprehensive 1000 Genomes-based genome-wide association meta-analysis of coronary artery disease

    Majid Nikpay;Anuj Goel;Hong-Hee Won;Leanne M. Hall

Frequent Co-Authors

Richard B. Devereux
Richard B. Devereux Cornell University
Björn Dahlöf
Björn Dahlöf Sahlgrenska University Hospital
Kristian Wachtell
Kristian Wachtell Cornell University
Sverre E. Kjeldsen
Sverre E. Kjeldsen University of Oslo
Veikko Salomaa
Veikko Salomaa Finnish Institute for Health and Welfare
Markus Perola
Markus Perola Finnish Institute for Health and Welfare
Stevo Julius
Stevo Julius University of Michigan–Ann Arbor
Peter M. Okin
Peter M. Okin Cornell University
Hans Wedel
Hans Wedel University of Gothenburg

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring medical studies in the USA, online degree programs offer flexible pathways to meet different career goals. Many students opt for accelerated dnp programs to quickly advance to leadership roles in nursing. These programs are designed for working nurses who want to obtain their Doctor of Nursing Practice in less time.

For those concerned about program difficulty, resources like easiest dnp program reddit can provide real-world insights and student experiences to help you choose the right fit. If you’re interested in a faster entry into nursing, consider 9 month lpn program options. These allow students to become Licensed Practical Nurses quickly—ideal for those seeking immediate, hands-on healthcare roles.

Specialized options are also available, such as psych nurse practitioner programs, which prepare graduates for advanced psychiatric care. Overall, online degrees and fast-track pathways can help streamline your journey in medicine, offering flexibility and career advancement suited to your goals.

Best Scientists Citing Markku S. Nieminen

Trending Scientists